Alnylam Pharmaceuticals, Inc. (0HD2.L)
USD 255.29
(-2.5%)
USD 255.29
(-2.5%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 3.82 Billion USD | 7.99% |
| 2022 | 3.54 Billion USD | -2.66% |
| 2021 | 3.64 Billion USD | 6.93% |
| 2020 | 3.4 Billion USD | 42.25% |
| 2019 | 2.39 Billion USD | 52.09% |
| 2018 | 1.57 Billion USD | -21.05% |
| 2017 | 1.99 Billion USD | 57.96% |
| 2016 | 1.26 Billion USD | -8.92% |
| 2015 | 1.38 Billion USD | 28.43% |
| 2014 | 1.07 Billion USD | 156.72% |
| 2013 | 420.53 Million USD | 46.26% |
| 2012 | 287.52 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 3.82 Billion USD | -0.14% |
| 2024 Q3 | 4.2 Billion USD | 4.87% |
| 2024 Q2 | 4 Billion USD | 4.84% |
| 2023 Q4 | 3.82 Billion USD | -0.24% |
| 2023 Q3 | 3.83 Billion USD | 12.83% |
| 2023 Q2 | 3.4 Billion USD | 0.31% |
| 2023 Q1 | 3.39 Billion USD | -4.35% |
| 2023 FY | 3.82 Billion USD | 7.99% |
| 2022 Q3 | 3.53 Billion USD | 6.15% |
| 2022 Q2 | 3.33 Billion USD | -3.0% |
| 2022 Q1 | 3.43 Billion USD | -5.76% |
| 2022 FY | 3.54 Billion USD | -2.66% |
| 2022 Q4 | 3.54 Billion USD | 0.31% |
| 2021 Q3 | 3.47 Billion USD | -1.06% |
| 2021 FY | 3.64 Billion USD | 6.93% |
| 2021 Q4 | 3.64 Billion USD | 4.92% |
| 2021 Q2 | 3.5 Billion USD | 7.81% |
| 2021 Q1 | 3.25 Billion USD | -4.46% |
| 2020 Q2 | 3.37 Billion USD | 48.02% |
| 2020 Q4 | 3.4 Billion USD | 3.02% |
| 2020 FY | 3.4 Billion USD | 42.25% |
| 2020 Q1 | 2.27 Billion USD | -4.82% |
| 2020 Q3 | 3.3 Billion USD | -1.99% |
| 2019 Q3 | 2.54 Billion USD | -6.43% |
| 2019 Q1 | 2.01 Billion USD | 27.89% |
| 2019 FY | 2.39 Billion USD | 52.09% |
| 2019 Q4 | 2.39 Billion USD | -5.76% |
| 2019 Q2 | 2.71 Billion USD | 34.88% |
| 2018 Q2 | 1.78 Billion USD | -6.95% |
| 2018 Q1 | 1.92 Billion USD | -3.59% |
| 2018 FY | 1.57 Billion USD | -21.05% |
| 2018 Q4 | 1.57 Billion USD | -6.02% |
| 2018 Q3 | 1.67 Billion USD | -6.36% |
| 2017 FY | 1.99 Billion USD | 57.96% |
| 2017 Q4 | 1.99 Billion USD | 46.86% |
| 2017 Q3 | 1.35 Billion USD | -5.3% |
| 2017 Q2 | 1.43 Billion USD | 26.49% |
| 2017 Q1 | 1.13 Billion USD | -10.21% |
| 2016 Q4 | 1.26 Billion USD | -3.82% |
| 2016 FY | 1.26 Billion USD | -8.92% |
| 2016 Q1 | 1.31 Billion USD | -5.02% |
| 2016 Q2 | 1.38 Billion USD | 4.95% |
| 2016 Q3 | 1.31 Billion USD | -5.01% |
| 2015 Q4 | 1.38 Billion USD | -3.46% |
| 2015 Q3 | 1.43 Billion USD | -6.18% |
| 2015 Q2 | 1.53 Billion USD | -6.02% |
| 2015 Q1 | 1.62 Billion USD | 50.87% |
| 2015 FY | 1.38 Billion USD | 28.43% |
| 2014 Q2 | 1.03 Billion USD | -4.41% |
| 2014 Q3 | 986.35 Million USD | -4.48% |
| 2014 Q4 | 1.07 Billion USD | 9.45% |
| 2014 Q1 | 1.08 Billion USD | 156.89% |
| 2014 FY | 1.07 Billion USD | 156.72% |
| 2013 FY | 420.53 Million USD | 46.26% |
| 2013 Q2 | 462.55 Million USD | -1.91% |
| 2013 Q3 | 447.5 Million USD | -3.25% |
| 2013 Q4 | 420.53 Million USD | -6.03% |
| 2013 Q1 | 471.57 Million USD | 64.02% |
| 2012 Q4 | 287.52 Million USD | 0.0% |
| 2012 FY | 287.52 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| uniQure N.V. | 831.68 Million USD | -360.494% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | -308.687% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | -392.348% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -2214.071% |
| bluebird bio, Inc. | 619.16 Million USD | -518.56% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -2943.355% |
| Imunon, Inc. | 21.91 Million USD | -17373.62% |
| Editas Medicine, Inc. | 499.15 Million USD | -667.276% |
| IQVIA Holdings Inc. | 26.68 Billion USD | 85.646% |
| Mettler-Toledo International Inc. | 3.35 Billion USD | -14.136% |
| Myriad Genetics, Inc. | 1.19 Billion USD | -219.503% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | -17.792% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | -171.82% |
| Verastem, Inc. | 149.71 Million USD | -2458.062% |
| Walgreens Boots Alliance, Inc. | 81.03 Billion USD | 95.274% |
| Waters Corporation | 4.62 Billion USD | 17.225% |
| Thermo Fisher Scientific Inc. | 98.72 Billion USD | 96.121% |
| Biogen Inc. | 26.84 Billion USD | 85.733% |
| Nektar Therapeutics | 398.03 Million USD | -862.202% |
| Perrigo Company plc | 10.8 Billion USD | 64.568% |
| Dynavax Technologies Corporation | 997.09 Million USD | -284.103% |
| Illumina, Inc. | 10.11 Billion USD | 62.122% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -13446.36% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | -390.789% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -1621.248% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -5730.233% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 44.021% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -2216.647% |
| Evolus, Inc. | 188.99 Million USD | -1926.413% |
| Adicet Bio, Inc. | 207.29 Million USD | -1747.551% |
| Aclaris Therapeutics, Inc. | 197.4 Million USD | -1840.113% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 88.422% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | -1761.008% |
| FibroGen, Inc. | 423.52 Million USD | -804.278% |
| Agilent Technologies, Inc. | 10.76 Billion USD | 64.416% |
| OPKO Health, Inc. | 2.01 Billion USD | -90.38% |
| Homology Medicines, Inc. | 47.05 Million USD | -8038.81% |
| Geron Corporation | 394.07 Million USD | -871.863% |
| Exelixis, Inc. | 2.94 Billion USD | -30.164% |
| Viking Therapeutics, Inc. | 368.49 Million USD | -939.344% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -2380.717% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | -194.385% |
| Zoetis Inc. | 14.28 Billion USD | 73.191% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | -551.079% |
| Abeona Therapeutics Inc. | 64 Million USD | -5884.001% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 83.151% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -6745.306% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | -28.087% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | -17.316% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | -516.215% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | -120.963% |
| Blueprint Medicines Corporation | 1.04 Billion USD | -265.011% |
| Insmed Incorporated | 1.32 Billion USD | -187.996% |
| TG Therapeutics, Inc. | 329.58 Million USD | -1062.024% |
| Incyte Corporation | 6.78 Billion USD | 43.53% |
| Emergent BioSolutions Inc. | 1.83 Billion USD | -108.724% |